Brain

Onsite Launches Outpatient Services at Onsite Wellness House in Nashville

Onsite Wellness House brings the best of Onsite and Milestones to those in Nashville and surrounding areas while minimizing disruption…

10 months ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…

10 months ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses…

10 months ago

Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference

NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company…

10 months ago

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of…

10 months ago

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer’s Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

10 months ago

We Heart You: Recovery in Our Community Event 2024

What: We Heart You: Recovery in Our Community EventWhen: Wednesday, March 13, 12:00-5:00 PM(Welcome at 12:30 PM, Keynote speaker from…

10 months ago

Zeto Adds New Chief Financial Officer to Accelerate Growth

SANTA CLARA, CA / ACCESSWIRE / March 6, 2024 / Zeto, Inc., a commercial-stage medical technology company transforming EEG brain…

10 months ago

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,…

10 months ago

Nalu Medical, Inc. Closes $85 Million Series E Round

B Capital invests incremental $20M; previously raised $65M led by Novo Holdings with participation from existing investors Equity investment to…

10 months ago